Selank: anxiolytic peptide, Russian Phase II evidence, and what that evidence does and doesn't prove.
Selank is a synthetic heptapeptide analog of tuftsin (Thr-Lys-Pro-Arg) developed at the Russian Academy of Sciences and registered by the Russian Ministry of Health in 2009 for generalised anxiety disorder. Its primary pharmacological profile is anxiolytic — not nootropic in the strict sense — though the Russian literature reports secondary cognitive benefits through anxiety reduction and improved attentional stability. It is one of the more scientifically coherent peptides in the research-chemical space, with a genuine mechanism and a real clinical programme, situated in a literature base that has not been independently replicated in the West.
- Heptapeptide Thr-Lys-Pro-Arg-Pro-Gly-Pro: tuftsin (endogenous tetrapeptide Thr-Lys-Pro-Arg) plus a C-terminal Pro-Gly-Pro stability extension, identical to the extension strategy used in Semax.
- Registered by the Russian Ministry of Health in 2009 for generalised anxiety disorder (GAD) and neurasthenia. Russian 0.15% intranasal formulation (Selank nasal drops) is the clinical-use form.
- Primary mechanism: positive allosteric modulation of GABA-A receptors; secondary serotonergic modulation. This is a conventional anxiolytic mechanism (shared class with benzodiazepines at GABA-A, though the binding site and degree of modulation differ substantially).
- Immunomodulatory activity reported via tuftsin receptor binding — tuftsin is a naturally occurring leukocyte-activating tetrapeptide; Selank preserves this component of the parent molecule's activity.
- Russian Phase II trial in GAD (Zozulya et al., 2008) reported significant reduction in anxiety scores vs placebo without sedation or dependence signals; this is the primary efficacy reference for this compound.
- No published Western (non-Russian) randomised controlled trial as of April 2026. Not FDA-approved, not EMA-approved.
What Selank actually is
Tuftsin is a naturally occurring endogenous tetrapeptide (Thr-Lys-Pro-Arg) cleaved from the Fc fragment of immunoglobulin G. It is one of the few endogenous peptides with both central and peripheral activity — activating phagocytes and natural killer cells (immunological activity) and having CNS effects that include modest anxiolytic action in rodent models.
The Ashmarin group at the Institute of Molecular Genetics designed Selank by adding the Pro-Gly-Pro tripeptide extension to tuftsin's C-terminus, the same stability-enhancement strategy used in the Semax design from the same laboratory. This extension significantly improves resistance to carboxypeptidase degradation, extending the half-life and CNS-active period compared to the parent tuftsin molecule.
The result is a heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro) that the Russian literature reports as having substantially stronger and more sustained anxiolytic effects than tuftsin, delivered intranasally at concentrations where the peptide can distribute to limbic and cortical targets via olfactory nerve projections. Russian clinical formulations are 0.15% nasal drops, delivering approximately 150 mcg per mL.
Mechanism: GABA-A, serotonin, and immune modulation
Three mechanistic pathways have been described in the Russian pharmacological literature for Selank:
- GABA-A receptor modulation. Seredenin and Voronin (2009) characterised Selank as a positive allosteric modulator of GABA-A receptors. The GABA-A receptor is the primary target of benzodiazepines and other classic anxiolytics; positive allosteric modulation enhances the inhibitory effect of endogenous GABA. Selank's modulation is described as weaker and more selective than benzodiazepines — consistent with the lack of reported sedation or dependence in the Russian clinical studies — but mechanistically in the same class. This is the most scientifically credible mechanistic claim for Selank.
- Serotonergic modulation. Russian studies describe increased serotonin turnover in cortical and limbic regions following Selank administration. This would be consistent with the reported mood-stabilising effects distinct from pure anxiolysis. The degree of serotonergic effect and its relationship to the GABA-A activity is not quantitatively characterised in the published literature.
- Immunomodulatory activity. Selank retains the tuftsin tetrapeptide as its N-terminal sequence, preserving tuftsin's leukocyte-activating and immunoregulatory properties. Russian studies report normalisation of pro-inflammatory cytokine profiles in anxiety patients — claimed as a secondary benefit, particularly in the context of stress-immune axis dysregulation common in generalised anxiety disorder.
The Russian clinical evidence
The primary efficacy reference for Selank is the Zozulya et al. (2008) study published in Zhurnal Nevrologii i Psikhiatrii. This was a controlled study in patients with generalised anxiety disorder and neurasthenia (a diagnostic category used in Russian psychiatry). The study reported statistically significant reductions in Hamilton Anxiety Scale (HAM-A) scores in the Selank group versus placebo, without sedation, without dependence signals at 14-day follow-up, and with an immunomodulatory profile (normalised cytokine ratios) also observed.
Akhapkina and Akhapkin (2013) published a clinical review in Zhurnal Nevrologii i Psikhiatrii covering the Selank clinical experience and reporting a favourable safety profile across the Russian trial database.
The Russian Ministry of Health registration (2009) is based on this clinical programme. The registration covers GAD and neurasthenia and specifies intranasal administration of the 0.15% formulation.
Selank and sleep — the cross-cluster bridge
The relationship between anxiety and sleep disruption is well-established: GAD is a major driver of sleep-onset and sleep-maintenance insomnia. Selank's anxiolytic mechanism creates a plausible indirect pathway to sleep benefit — reduced evening anxiety and reduced rumination may improve sleep onset and reduce nighttime cortical arousal. The Russian literature includes reports of sleep improvement as a secondary endpoint in anxiety trials.
This mechanistic overlap is why our Sleep & Circadian pillar includes a dedicated spoke for Selank's sleep effects (spoke 6.5 in that cluster). Researchers interested in Selank primarily for sleep improvement should read that spoke: the mechanism for sleep benefit is likely indirect (through anxiety reduction and autonomic calming), not a direct hypnotic mechanism. Selank does not appear to work like benzodiazepine hypnotics or like DSIP, which has a more specific proposed sleep-promoting mechanism.
For the anxiety-specific evidence in detail, our Selank for anxiety spoke provides the full clinical analysis. For the comparison with Semax across all dimensions, see our Semax vs Selank head-to-head page.
Selank vs other anxiolytic options
| Compound | Mechanism class | Primary effect | Human RCT evidence | Sedation risk | Dependence risk |
|---|---|---|---|---|---|
| Selank | GABA-A PAM + serotonergic | Anxiolysis, mood stabilisation | Russian Phase II (GAD) | Low (reported) | Not reported |
| Semax | ACTH-analog / BDNF upregulator | Cognitive enhancement, neuroprotection | Russian Phase II–III (stroke) | None | None reported |
| Benzodiazepines | GABA-A BZD site agonist | Anxiolysis, sedation | Yes — extensive | High | High |
| SSRIs (e.g. escitalopram) | Serotonin reuptake inhibitor | Anxiolysis (GAD), depression | Yes — Phase III, FDA-approved | Low | Low |
| Buspirone | 5-HT1A partial agonist | Anxiolysis (GAD) | Yes — Phase III, FDA-approved | Low | None |
The comparison table highlights Selank's unique positioning: anxiolytic without the sedation profile of benzodiazepines, but also without the extensive Western trial base of approved alternatives. Researchers evaluating Selank against established anxiolytics must weigh a plausible mechanism and Russian Phase II evidence against the lack of Western replication and the absence of long-term safety data that regulatory approvals require.
Regulatory status
Selank is registered by the Russian Ministry of Health (registration number LS-000614) for generalised anxiety disorder and neurasthenia. This registration covers the 0.15% intranasal formulation. It is not approved by the FDA, EMA, or any Western regulatory body.
In the United States, Selank exists as an unscheduled research chemical — not a scheduled controlled substance, but not approved for human use or legal for compounding pharmacies to prepare and dispense. It is sold under a research-use-only framing by research-chemical vendors. Any vendor claiming Selank is "approved," "legal for human use," or FDA-cleared in the US is misrepresenting the regulatory situation.
Where to read further
Selected primary literature:
- Seredenin SB, Voronin MV. "Neuroreceptor mechanisms of the anxiolytic action of selank." Eksperimental'naia i Klinicheskaia Farmakologiia. 2009; 72(4):3–6. [Russian]
- Zozulya AA, Neznamov GG, Siuniakov TS, et al. "Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia." Zhurnal Nevrologii i Psikhiatrii. 2008; 108(4):38–48. [Russian]
- Akhapkina VI, Akhapkin RV. "Selank: clinical efficacy and safety aspects." Zhurnal Nevrologii i Psikhiatrii. 2013; 113(10):82–88. [Russian]